Literature DB >> 17879951

Association of IGF-1 and IGFBP-3 with lower urinary tract symptoms in the third national health and nutrition examination survey.

Sabine Rohrmann1, Edward Giovannucci, Ellen Smit, Elizabeth A Platz.   

Abstract

BACKGROUND: Benign growth of the prostate is thought to contribute to lower urinary tract symptoms (LUTS) in older men. It is, however, unclear which factors induce prostate growth in these men. We examined the association of insulin-like growth factor (IGF)-1 and its major binding protein IGFBP-3 with LUTS in a representative US study.
METHODS: We included men 60 years and older who participated in the morning session of the Third National Health and Examination Survey (NHANES III) between 1988 and 1994. Men were classified as cases (n = 91) if they reported at least three of four LUTS (nocturia, incomplete emptying, hesitancy, or weak stream) but had not had non-cancer prostate surgery in the past. Controls were men without symptoms and surgery (n = 220). All results were weighted to account for sampling probability in NHANES III. IGF-1 and IGFBP-3 were measured by ELISA and IRMA, respectively.
RESULTS: After mutual adjustment, men in the highest tertile of serum IGF-1 concentration had a non-significantly higher odds of LUTS than men in the lowest tertile (odds ratio (OR) = 3.20; 95% confidence interval (CI) 0.89-11.4; p-trend = 0.09]. A high concentration of IGFBP-3 was inversely related to the odds of LUTS (OR = 0.25; 95% CI 0.08-0.81; p-trend = 0.02).
CONCLUSION: A high IGFBP-3 level might affect LUTS by decreasing the bioavailability of IGF-1 or independent of IGF-1 by up-regulating apoptosis, and, thus, limiting its growth promoting effects on the prostate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17879951     DOI: 10.1002/pros.20659

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.

Authors:  Honglin Ding; Ning Li; Xiaoning He; Bing Liu; Liming Dong; Yili Liu
Journal:  Int Urol Nephrol       Date:  2017-07-29       Impact factor: 2.370

2.  Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia.

Authors:  Congyun Xu; Yan Xu; Zhou Shen; Hangcheng Zhou; Jun Xiao; Tao Huang
Journal:  Int Urol Nephrol       Date:  2018-02-19       Impact factor: 2.370

Review 3.  Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity.

Authors:  Anne K Mongiu; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

4.  Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium.

Authors:  C Bosetti; V Rosato; D Li; D Silverman; G M Petersen; P M Bracci; R E Neale; J Muscat; K Anderson; S Gallinger; S H Olson; A B Miller; H Bas Bueno-de-Mesquita; G Scelo; V Janout; I Holcatova; P Lagiou; D Serraino; E Lucenteforte; E Fabianova; P A Baghurst; W Zatonski; L Foretova; E Fontham; W R Bamlet; E A Holly; E Negri; M Hassan; A Prizment; M Cotterchio; S Cleary; R C Kurtz; P Maisonneuve; D Trichopoulos; J Polesel; E J Duell; P Boffetta; C La Vecchia; P Ghadirian
Journal:  Ann Oncol       Date:  2014-07-23       Impact factor: 32.976

5.  Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.

Authors:  Marian L Neuhouser; Jeannette Schenk; Yoon Ju Song; Catherine M Tangen; Phyllis J Goodman; Michael Pollak; David F Penson; Ian M Thompson; Alan R Kristal
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

6.  Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention.

Authors:  Firas Abdollah; Alberto Briganti; Nazareno Suardi; Fabio Castiglione; Andrea Gallina; Umberto Capitanio; Francesco Montorsi
Journal:  Korean J Urol       Date:  2011-08-22

7.  Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.

Authors:  Weiqiang Li; Robert J Klein
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-11-20       Impact factor: 5.554

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.